Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
Acumen Pharmaceuticals reported Q3 2026 net loss of $25.4 million and confirmed topline results from its ALTITUDE-AD Phase 2 study of sabirnetug in early Alzheimer's disease are expected in November 2026. Cash, cash equivalents and marketable securities stood at $78.6 million as of September 30, 2026, down from $110.2 million at June 30, and are expected to fund operations only into early 2027.
Key figures
- Net loss
- 25369000
- Ga expense
- 4700000
- Rd expense
- 21113000
- Cash runway
- into early 2027
- Trial enrollment
- 542
- Loss from operations
- 25813000
- Cash and marketable securities
- 78600000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.